James H. Liu

TL;DR: This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cancer while producing endometrial cancer rates similar to placebo, and provides additional support for caution in the use of continuous combined hormones.

TL;DR: The postmenopausal hormone therapy (PHT) component of the Women’s Health Initiative (WHI) is composed of two randomized, placebo-controlled, double-blind trials in post menopausal women aged 50 to 79 years at initial screening, testing the effects of estrogen alone (E-alone) and estrogen plus progestin (E P) on coronary heart disease (CHD) as the primary outcome, hip and other fractures and colorectal cancer as secondary outcomes.

TL;DR: Dietary inclusion of whole soy foods containing 60 mg/d of isoflavones results in significant serum levels of phytoestrogens and reductions in several key clinical risk factors for CVD and osteoporosis in normal postmenopausal women.

TL;DR: The drug delivery system can be a tampon device (42), vaginal ring, pessary, tablet, suppository, vaginal sponge, bioadhesive tablet, bio-adhesive microparticle, cream lotion, foam, ointment, paste solution, or gel as mentioned in this paper.

TL;DR: This Position Statement has been endorsed by the International Menopause Society, the Endocrine Society of Australia, and the Royal Australian and New Zealand College of Obstetricians and Gynecologists.